NICE recommends Kyntheum as a treatment for plaque psoriasis-. Leo Pharma.
The National Institute for Health and Care Excellence (NICE),has recommended Kyntheum (brodalumab), from Leo Pharma, to treat adult plaque psoriasis patients who have not responded to standard systemic therapies or who are unable to take them and for those who have a Psoriasis Area and Severity Index (PASI) score of 10 or more. The recommendation however, is dependent on the continued provision of a patient access scheme, under which the drug is offered at an undisclosed discount to the NHS.
Along with the discount, the recommendation was supported by data from the AMAGINE phase III clinical trial programme, which consisted of three clinical trials with a total of 4,373 patients. All three studies evaluated the efficacy and safety of different doses of Kyntheum compared to placebo and data showed that the drug had an �acceptable� safety profile.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.